EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer Read more
New Novartis data show Piqray effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancer Read more
Punjab government, Roche Pharma and Niramai Health Analytix launch ‘Pink Project’ initiative Read more
Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients with HER2-low metastatic breast cancer Read more